The role of antileukotriene therapy in COPD management: a systematic review and meta-analysis of randomized controlled trials
Authors:
- Mostafa SalimiMSMostafa Salimi
- Majid MirsadraeeMMMajid Mirsadraee
- Ghazal YazdaniGYGhazal Yazdani
- Narges MahmoudiNMNarges Mahmoudi
Open Access
- 2 July 2026
- journal article
- review article
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 20 (1)
Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is a prevalent lung condition that impairs breathing and daily activities, manifesting symptoms such as a persistent cough, shortness of breath, and chest tightness. Antileukotrienes, including Montelukast, Zafirlukast, and Zileuton, are used to manage inflammation in asthma; however, according to the 2025 GOLD reports, their efficacy in treating COPD remains unclear. This systematic review and meta-analysis aim to evaluate the role of antileukotriene therapy in patients with COPD. Method: This systematic review was reported in accordance with the PRISMA guidelines. In July 2023, a comprehensive search was conducted across Scopus, Web of Science, PubMed, Cochrane Library, and Embase. The review included only randomized controlled trials that compared anti-leukotriene agents with a placebo. A meta-analysis was performed on Forced Expiratory Volume in 1 s(FEV1), Leukotriene B4(LTB4), and Myeloperoxidase(MPO), utilizing standardized mean differences(SMD) with a 95% confidence interval(CI). C-reactive protein(CRP), quality of life and adverse events data were summarized narratively. Results: This meta-analysis encompassed nine randomized controlled trials involving a total of 506 participants. The findings indicated that anti-leukotriene therapy led to a significant overall improvement in FEV1 (SMD = 0.63, 95%CI 0.15 to 1.11, p = 0.01), although high heterogeneity was noted(I 2 = 83%). A subgroup analysis focusing specifically on leukotriene receptor antagonists revealed a more consistent and potent effect on FEV1 (SMD = 1.00, 95%CI 0.75 to 1.25, p < 0.001) with low heterogeneity. Notably, both Montelukast(SMD = 1.15) and Zafirlukast(SMD = 0.75) displayed significant benefits. In contrast, no significant improvements were found in the inflammatory markers LTB4 (SMD=-0.42) or MPO (SMD=-0.14). CRP results were inconclusive, while quality of life scores showed improvement in the montelukast groups. Adverse events were comparable between groups or reduced in the experimental group. Conclusion: Analysis indicates that anti-leukotriene therapy, particularly with Montelukast and Zafirlukast, may lead to a modest improvement in lung function and quality of life. Subgroup analyses suggest a potential benefit specifically for Montelukast, although this requires further confirmation. In contrast, Zileuton, which operates via a different mechanism, did not demonstrate any beneficial effects. Given the limitations in sample size and heterogeneity, these findings should be considered exploratory, and additional research is essential to validate these results in larger studies.Keywords
This publication has 16 references indexed in Scilit:
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviewsBMJ, 2021
- Epidemiology of Chronic Obstructive Pulmonary DiseaseClinics in Chest Medicine, 2020
- Understanding the impact of symptoms on the burden of COPDRespiratory Research, 2017
- The Effectiveness of Anti-leukotriene Agents in Patients with COPD: A Systemic Review and Meta-analysisLung, 2015
- Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary diseasePulmonary Pharmacology & Therapeutics, 2008
- Short-term effects of montelukast in stable patients with moderate to severe COPDRespiratory Medicine, 2005
- Montelukast attenuates the airway response to hypertonic saline in moderate-to-severe COPDEuropean Respiratory Journal, 2003
- Bronchodilator effect of zafirlukast in subjects with chronic obstructive pulmonary diseasePulmonary Pharmacology & Therapeutics, 2003
- A Randomized, Placebo-Controlled Trial of a Leukotriene Synthesis Inhibitor in Patients With COPDChest, 2002
- Comparison of the Bronchodilating Effect of Salmeterol and Zafirlukast in Combination with That of Their Use as Single Treatments in Asthma and Chronic Obstructive Pulmonary DiseaseRespiration, 2001